A method may include wet ball milling a plurality of iron nitride nanoparticles in the presence of a surface active agent to modify a surface of the plurality of iron nitride nanoparticles and form a plurality of surface-modified iron nitride nanoparticles for a variety of biomedical applications and soft magnetic materials related applications.

A multimodal PET (positron emission tomography)/MRI (magnetic resonance imaging) contrast agent, a process of synthesizing said PET/MRI contrast agent, and a pharmaceutical formulation comprising said PET/MRI contrast agent are disclosed. The PET/MRI contrast agent comprises a magnetic signal generating core, and a coating portion formed at least partially over a surface of said magnetic signal generating core, wherein the coating portion comprises a plurality of layers, including an inner layer having a functionalized surface, and an outer layer in the form of a radionuclide electrolessly plated layer formed on said functionalized surface.

Nanoparticle-sized magnetic absorption enhancers (MAEs) exhibiting a controlled response to a magnetic field, including a controlled mechanical response and an inductive thermal response. The MAEs have a magnetic material that exhibits inductive thermal response to the magnetic field and is embedded in a coating, such that the MAE conforms to a particular shape, e.g., hemisphere, dome or shell, chosen to produce the controlled mechanical response. A targeting moiety for specifically binding the MAE to a pathogen target is also provided. The MAEs can be bound by a flexible linker to promote the desired mechanical response, which includes interactions between MAEs that are not bound to any pathogen target for the purpose of forming spheres, spherical shells, or generally spherical dimers to contain the thermal energy produced and to thus reduce collateral healthy tissue damage during hyperthermic treatment.

Composite particles, each of which is obtained by forming, on the surface of a gadolinium oxide-containing particle, a cover film that contains a polymer obtained by polymerizing a monomer component containing a monomer having an ethylenically unsaturated bond; a macrophage imaging agent which contains the composite particles; and a method for producing composite particles, wherein a monomer component containing a monomer having an ethylenically unsaturated bond and gadolinium oxide-containing particles are mixed with each other, and after emulsifying the thus-obtained monomer component-containing mixture in water in the presence of a surfactant and a polymerization initiator in water, the monomer component is polymerized, thereby forming cover films on the surfaces of the gadolinium oxide-containing particles.

Disclosed herein are pharmacologically acceptable magnetic nanoparticles suitable for administration to a subject.

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein.

Surface-modified cell containing a cell and a conformal coating on the extracellular surface of the cell are described. The conformal coating contains two or more layers containing particles (e.g. nanoparticles) or macromolecules. The cell is an islet cell, a B cell, or a T cell. The macromolecules or particles are formed from zwitterionic polymers. Covalent linkages are employed to link the particles or macromolecules to a cell surface molecule containing an abiotic functional group, or between macromolecules and/or particles in adjacent layers. Also described are methods of making and using a surface-modified cell.

Disclosed herein are pharmacologically acceptable magnetic nanoparticles suitable for administration to a subject.

The invention relates to a polymer comprising a crosslinked matrix, the matrix being based on at least: a) 20 to 90% hydrophilic monomer; b) 5 to 50% radio-opaque halogenated monomer; c) 1 to 15% non-biodegradable hydrophilic crosslinking agent; and d) 0.1 to 10% transfer agent chosen among the alkyl halides and cycloaliphatic or aliphatic thiols having, in particular, 2 to 24 carbon atoms, and optionally having another functional group chosen among the amino, hydroxy and carboxy groups. The invention further relates to a pharmaceutical composition comprising at least one polymer according to the invention, in association with a pharmaceutically acceptable vehicle, advantageously for a parenteral administration. The invention further relates to a kit comprising a pharmaceutical composition comprising the polymer according to the invention in association with a pharmaceutically acceptable vehicle for a parenteral administration, and an injection means.

The present technology relates to the field of drug delivery. For example, the present technology provides methods of delivering a therapeutic to a cell where the method includes administering to a cancer cell a drug delivery composition. In this exemplary method, the drug deliver composition includes a (super)paramagnetic iron oxide nanoparticle core, where the nanoparticle core includes a coat non-covalently attached to a therapeutic, and the coat includes at least one of poly(acrylic acid), carboxymethyl dextran, and polyglucose sorbitol carboxymethylether.